Gabapentin

This exact human hard-capsule family has sourced current registrations in Georgia and EU/EEA, an active current regulator-hosted SmPC and no exact GB or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Canine evidence is mixed and role-dependent. Oral pharmacokinetics support rapid absorption but a short half-life; a small uncontrolled refractory-epilepsy study found benefit in some dogs, while randomized pain studies are limited and have not consistently separated gabapentin from placebo or strong background analgesia. It is therefore an adjunct with a predefined response target, not a default standalone analgesic or anticonvulsant.

Sedation and ataxia are the principal dose-limiting veterinary effects; rapid dose escalation, concurrent opioids or other CNS depressants can increase impairment and respiratory risk. Renal elimination, short canine half-life and withdrawal or breakthrough-seizure risk make dose interval, kidney function and gradual discontinuation clinically important. Exact-product long-term safety data in dogs are absent.

A whole 300 mg capsule can fit some medium-to-large dogs, is stable and easy to store, but the exact label requires swallowing it whole. It is too coarse for many small-dog starting doses or renal adjustments, and the short canine half-life can require repeated daily administration; a 100 mg or validated compounded form is often more practical.

This exact human hard-capsule family has sourced current registrations in Georgia and EU/EEA, an active current regulator-hosted SmPC and no exact GB or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Feline evidence is strongest for short-term pre-visit fear and stress reduction, supported by several blinded randomized studies, usually with 50-200 mg total doses. A small randomized osteoarthritis study found owner-perceived mobility improvement but lower measured activity and frequent sedation, so chronic analgesic efficacy is less certain; seizure evidence is indirect. Benefit must be judged separately for the intended role.

Transient sedation, ataxia, weakness, hypersalivation and occasional vomiting are documented in feline trials and can alter gait and neurological examination. Cats with CKD have substantially higher dose-normalised concentrations, requiring reduction and longer observation. Chronic exposure adds accumulation and withdrawal concerns, and these exact high-strength human capsules have no feline tolerability study.

The exact label requires this 300 mg hard capsule to be swallowed whole. That unit exceeds the 50-200 mg total doses studied for most feline pre-visit protocols and greatly exceeds many weight-based chronic-pain increments; it cannot be quartered accurately. A lower-strength capsule or pharmacy-validated xylitol-free compound is normally required.

This exact human hard-capsule family has sourced current registrations in Georgia and EU/EEA, an active current regulator-hosted SmPC and no exact GB or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Canine evidence is mixed and role-dependent. Oral pharmacokinetics support rapid absorption but a short half-life; a small uncontrolled refractory-epilepsy study found benefit in some dogs, while randomized pain studies are limited and have not consistently separated gabapentin from placebo or strong background analgesia. It is therefore an adjunct with a predefined response target, not a default standalone analgesic or anticonvulsant.

Sedation and ataxia are the principal dose-limiting veterinary effects; rapid dose escalation, concurrent opioids or other CNS depressants can increase impairment and respiratory risk. Renal elimination, short canine half-life and withdrawal or breakthrough-seizure risk make dose interval, kidney function and gradual discontinuation clinically important. Exact-product long-term safety data in dogs are absent.

A whole 400 mg capsule may fit selected large-dog regimens but is a coarse unit for titration, small dogs and renal adjustment, and the exact label requires swallowing it whole. Repeated dosing with a short canine half-life increases treatment burden; a lower strength is usually preferable when precise response-guided adjustment is needed.

This exact human hard-capsule family has sourced current registrations in Georgia and EU/EEA, an active current regulator-hosted SmPC and no exact GB or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Feline evidence is strongest for short-term pre-visit fear and stress reduction, supported by several blinded randomized studies, usually with 50-200 mg total doses. A small randomized osteoarthritis study found owner-perceived mobility improvement but lower measured activity and frequent sedation, so chronic analgesic efficacy is less certain; seizure evidence is indirect. Benefit must be judged separately for the intended role.

Transient sedation, ataxia, weakness, hypersalivation and occasional vomiting are documented in feline trials and can alter gait and neurological examination. Cats with CKD have substantially higher dose-normalised concentrations, requiring reduction and longer observation. Chronic exposure adds accumulation and withdrawal concerns, and these exact high-strength human capsules have no feline tolerability study.

The exact label requires this 400 mg hard capsule to be swallowed whole. It is even further from the 50-200 mg total feline pre-visit evidence and from typical weight-based chronic dosing, so the exact presentation is generally unsuitable for accurate feline use without professional reformulation; informal powder division is not acceptable.

This exact human hard-capsule family has sourced current registrations in Georgia and GB, a current identifiable UK SmPC and no exact EU/EEA or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Canine evidence is mixed and role-dependent. Oral pharmacokinetics support rapid absorption but a short half-life; a small uncontrolled refractory-epilepsy study found benefit in some dogs, while randomized pain studies are limited and have not consistently separated gabapentin from placebo or strong background analgesia. It is therefore an adjunct with a predefined response target, not a default standalone analgesic or anticonvulsant.

Sedation and ataxia are the principal dose-limiting veterinary effects; rapid dose escalation, concurrent opioids or other CNS depressants can increase impairment and respiratory risk. Renal elimination, short canine half-life and withdrawal or breakthrough-seizure risk make dose interval, kidney function and gradual discontinuation clinically important. Exact-product long-term safety data in dogs are absent.

A whole 300 mg capsule can fit some medium-to-large dogs, is stable and easy to store, but the exact label requires swallowing it whole. It is too coarse for many small-dog starting doses or renal adjustments, and the short canine half-life can require repeated daily administration; a 100 mg or validated compounded form is often more practical.

This exact human hard-capsule family has sourced current registrations in Georgia and GB, a current identifiable UK SmPC and no exact EU/EEA or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Feline evidence is strongest for short-term pre-visit fear and stress reduction, supported by several blinded randomized studies, usually with 50-200 mg total doses. A small randomized osteoarthritis study found owner-perceived mobility improvement but lower measured activity and frequent sedation, so chronic analgesic efficacy is less certain; seizure evidence is indirect. Benefit must be judged separately for the intended role.

Transient sedation, ataxia, weakness, hypersalivation and occasional vomiting are documented in feline trials and can alter gait and neurological examination. Cats with CKD have substantially higher dose-normalised concentrations, requiring reduction and longer observation. Chronic exposure adds accumulation and withdrawal concerns, and these exact high-strength human capsules have no feline tolerability study.

The exact label requires this 300 mg hard capsule to be swallowed whole. That unit exceeds the 50-200 mg total doses studied for most feline pre-visit protocols and greatly exceeds many weight-based chronic-pain increments; it cannot be quartered accurately. A lower-strength capsule or pharmacy-validated xylitol-free compound is normally required.

This exact human hard-capsule family has sourced current registrations in Georgia and GB, a current identifiable UK SmPC and no exact EU/EEA or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Canine evidence is mixed and role-dependent. Oral pharmacokinetics support rapid absorption but a short half-life; a small uncontrolled refractory-epilepsy study found benefit in some dogs, while randomized pain studies are limited and have not consistently separated gabapentin from placebo or strong background analgesia. It is therefore an adjunct with a predefined response target, not a default standalone analgesic or anticonvulsant.

Sedation and ataxia are the principal dose-limiting veterinary effects; rapid dose escalation, concurrent opioids or other CNS depressants can increase impairment and respiratory risk. Renal elimination, short canine half-life and withdrawal or breakthrough-seizure risk make dose interval, kidney function and gradual discontinuation clinically important. Exact-product long-term safety data in dogs are absent.

A whole 400 mg capsule may fit selected large-dog regimens but is a coarse unit for titration, small dogs and renal adjustment, and the exact label requires swallowing it whole. Repeated dosing with a short canine half-life increases treatment burden; a lower strength is usually preferable when precise response-guided adjustment is needed.

This exact human hard-capsule family has sourced current registrations in Georgia and GB, a current identifiable UK SmPC and no exact EU/EEA or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Feline evidence is strongest for short-term pre-visit fear and stress reduction, supported by several blinded randomized studies, usually with 50-200 mg total doses. A small randomized osteoarthritis study found owner-perceived mobility improvement but lower measured activity and frequent sedation, so chronic analgesic efficacy is less certain; seizure evidence is indirect. Benefit must be judged separately for the intended role.

Transient sedation, ataxia, weakness, hypersalivation and occasional vomiting are documented in feline trials and can alter gait and neurological examination. Cats with CKD have substantially higher dose-normalised concentrations, requiring reduction and longer observation. Chronic exposure adds accumulation and withdrawal concerns, and these exact high-strength human capsules have no feline tolerability study.

The exact label requires this 400 mg hard capsule to be swallowed whole. It is even further from the 50-200 mg total feline pre-visit evidence and from typical weight-based chronic dosing, so the exact presentation is generally unsuitable for accurate feline use without professional reformulation; informal powder division is not acceptable.